Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
Betalutin (177Lu-satetraxetan-lilotomab)
i
Other names:
177Lu-DOTA-tetulomab, 177Lu-DOTA-HH1, Lymrit 37-05, HH1
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(4)
News
Trials
Company:
Nordic Nanovector
Drug class:
Ionizing radiation emitter, CD37 inhibitor
Related drugs:
‹
ibritumomab tiuxetan (3)
AAA614 (2)
Actinium-225 conjugated to daratumumab (2)
CLR 131 (2)
PNT2002 (2)
225Ac-FL-020 (1)
TLX250 (0)
177Lu-DTPA-omburtamab (0)
177Lu-LNC1003 (0)
177Lu-LNC1004 (0)
177Lu-LNC1010 (0)
177Lu-P17-087 (0)
177Lu-P17-088 (0)
177Lu-PSMA-R2 (0)
CYT 500 (0)
TLX591 (0)
90Y-NM600 (0)
TLX66 (0)
iodine I 131 tositumomab (0)
samarium-153 DOTMP (0)
EBTATE (0)
FF21101 (0)
ITM-91 (0)
epratuzumab Y-90 (0)
MVT-1075 (0)
186Re (0)
Radspherin (0)
lutetium-177 DOTA satoreotide (0)
67Cu MeCOSar octreotate (0)
Re (0)
BI 836826 (0)
PSB202 (0)
GEN-3009 (0)
ibritumomab tiuxetan (3)
AAA614 (2)
Actinium-225 conjugated to daratumumab (2)
CLR 131 (2)
PNT2002 (2)
225Ac-FL-020 (1)
TLX250 (0)
177Lu-DTPA-omburtamab (0)
177Lu-LNC1003 (0)
177Lu-LNC1004 (0)
177Lu-LNC1010 (0)
177Lu-P17-087 (0)
177Lu-P17-088 (0)
177Lu-PSMA-R2 (0)
CYT 500 (0)
TLX591 (0)
90Y-NM600 (0)
TLX66 (0)
iodine I 131 tositumomab (0)
samarium-153 DOTMP (0)
EBTATE (0)
FF21101 (0)
ITM-91 (0)
epratuzumab Y-90 (0)
MVT-1075 (0)
186Re (0)
Radspherin (0)
lutetium-177 DOTA satoreotide (0)
67Cu MeCOSar octreotate (0)
Re (0)
BI 836826 (0)
PSB202 (0)
GEN-3009 (0)
›
Associations
(4)
News
Trials
VERI cancer hierarchy
Reset Filters
ERBB3 expression
Renal Cell Carcinoma
ERBB3 expression
Renal Cell Carcinoma
177Lu-satetraxetan-lilotomab
Sensitive: D – Preclinical
177Lu-satetraxetan-lilotomab
Sensitive
:
D
177Lu-satetraxetan-lilotomab
Sensitive: D – Preclinical
177Lu-satetraxetan-lilotomab
Sensitive
:
D
ERBB3 expression
Prostate Cancer
ERBB3 expression
Prostate Cancer
177Lu-satetraxetan-lilotomab
Sensitive: D – Preclinical
177Lu-satetraxetan-lilotomab
Sensitive
:
D
177Lu-satetraxetan-lilotomab
Sensitive: D – Preclinical
177Lu-satetraxetan-lilotomab
Sensitive
:
D
ERBB3 expression
Colorectal Cancer
ERBB3 expression
Colorectal Cancer
177Lu-satetraxetan-lilotomab
Sensitive: D – Preclinical
177Lu-satetraxetan-lilotomab
Sensitive
:
D
177Lu-satetraxetan-lilotomab
Sensitive: D – Preclinical
177Lu-satetraxetan-lilotomab
Sensitive
:
D
ERBB3 expression
Ovarian Cancer
ERBB3 expression
Ovarian Cancer
177Lu-satetraxetan-lilotomab
Sensitive: D – Preclinical
177Lu-satetraxetan-lilotomab
Sensitive
:
D
177Lu-satetraxetan-lilotomab
Sensitive: D – Preclinical
177Lu-satetraxetan-lilotomab
Sensitive
:
D
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login